Skyhawk Therapeutics Has Advanced to the Multiple Ascending Dose Portion of its Phase 1 Study evaluating SKY-0515, a RNA-Targeting Small Molecule for Huntington’s Disease
SKY-0515 is a small molecule RNA splicing modifier developed through the company’s novel SKYSTAR® platform. Having successfully advanced through single asending dose, SKY-0515 is advancing into… อ่านเพิ่ม